<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462022000200138</article-id>
<article-id pub-id-type="doi">10.35366/108501</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Use of bedaquiline during pregnancy in a patient with MDR-TB. First case reported in Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Uso de bedaquilina durante el embarazo en una paciente con TB-MDR. Primer reporte de caso en México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-de la Cruz]]></surname>
<given-names><![CDATA[Paola L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Pérez]]></surname>
<given-names><![CDATA[Samuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laniado-Laborín]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Autonomous University of Baja California School of Medicine ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Autonomous University of Baja California School of Medicine ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>81</volume>
<numero>2</numero>
<fpage>138</fpage>
<lpage>140</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462022000200138&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462022000200138&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462022000200138&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Treatment of rifampin-resistant and multidrug-resistant tuberculosis in pregnant women is more complicated since little is known about the safety of second-line antituberculosis drugs during pregnancy and lactation. Drug-resistant tuberculosis, not having many options in the past, has been treated with regimens that include drugs with teratogenic potentials, such as thioamides and second-line injectables. Currently, there are new oral drugs, including bedaquiline, for the treatment of drug-resistant disease; however, the safety of bedaquiline during pregnancy and lactation has not been satisfactorily demonstrated so far. We report the first case in Mexico treated with a regimen that includes bedaquiline for multidrug-resistant tuberculosis during pregnancy, with favorable results, and without maternal-fetal complications.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El tratamiento de la tuberculosis resistente a la rifampicina y multirresistente en mujeres embarazadas es complicado ya que se sabe poco sobre la seguridad de los fármacos antituberculosis de segunda línea durante el embarazo y la lactancia. La tuberculosis farmacorresistente, no tenía muchas opciones en el pasado, se ha tratado con regímenes que incluyen medicamentos con potencial teratogénico, como tioamidas e inyectables de segunda línea. Actualmente, hay nuevos medicamentos orales, incluida la bedaquilina, para el tratamiento de enfermedades resistentes a los medicamentos de primera línea; sin embargo, la seguridad de la bedaquilina durante el embarazo y la lactancia no se ha demostrado satisfactoriamente hasta el momento. Reportamos el primer caso en México tratado con un régimen que incluye bedaquilina para la tuberculosis multirresistente durante el embarazo, con resultados favorables, y sin complicaciones materno-fetales.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[rifampin-resistant]]></kwd>
<kwd lng="en"><![CDATA[multidrug-resistant]]></kwd>
<kwd lng="en"><![CDATA[pregnancy]]></kwd>
<kwd lng="en"><![CDATA[bedaquiline]]></kwd>
<kwd lng="es"><![CDATA[tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[resistencia a la rifampicina]]></kwd>
<kwd lng="es"><![CDATA[multidrogo-resistencia]]></kwd>
<kwd lng="es"><![CDATA[embarazo]]></kwd>
<kwd lng="es"><![CDATA[bedaquilina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Tuberculosis country profiles [Internet]. Tuberculosis country profiles]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<source><![CDATA[Tuberculosis en las Américas. Informe regional 2020 [Internet]]]></source>
<year>2021</year>
<publisher-name><![CDATA[Pan American Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathad]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2012</year>
<volume>55</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1532-49</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueroa-Damián]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arredondo-Garc&#305;&#769;a]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neonatal Outcome of Children Born to Women with Tuberculosis]]></article-title>
<source><![CDATA[Arch Med Res [Internet]]]></source>
<year>2001</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>66-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Prats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[McIntire]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hesseling]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inclusion of key populations in clinical trials of new antituberculosis treatments: current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons]]></article-title>
<source><![CDATA[PLOS Med]]></source>
<year>2019</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dallman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chalco]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug&#8208;resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2009</year>
<volume>48</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1413-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[WHO consolidated guidelines on drug-resistant tuberculosis treatment [Internet]]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loveday]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sunkari]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Master]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hlangu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2021</year>
<volume>72</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1158-68</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marais]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Good outcomes in babies with in utero bedaquiline exposure]]></article-title>
<source><![CDATA[Clin Infect Dis [Internet]]]></source>
<year>2021</year>
<volume>72</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1169-70</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acquah]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr-Holland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Furin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loveday]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mudaly]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: a report of five patients]]></article-title>
<source><![CDATA[Pediatr Infect Dis J]]></source>
<year>2021</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e191-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
